{"gene":"ACE","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1970,"finding":"ACE (angiotensin-converting enzyme) functions as a dipeptidyl carboxypeptidase that converts angiotensin I to angiotensin II and inactivates bradykinin by cleaving C-terminal dipeptides.","method":"In vitro enzymatic assay with purified enzyme","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — foundational in vitro enzymatic characterization, replicated across decades","pmids":["4322742"],"is_preprint":false},{"year":1984,"finding":"Purified human ACE cleaves substance P at Phe8-Gly9 and Gly9-Leu10 (releasing C-terminal tri- and dipeptides in ~4:1 ratio) and cleaves neurotensin at Tyr11-Ile12; hydrolysis is Cl⁻-dependent, inhibited by captopril, and requires an active-site arginine residue (modification of Arg abolishes hydrolysis of substance P, bradykinin, and Bz-Gly-Phe-Arg by 80–93%).","method":"In vitro enzymatic assay with purified ACE; HPLC analysis; chemical modification of active-site arginine","journal":"Peptides","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with chemical mutagenesis of active site, multiple substrates tested","pmids":["6208535"],"is_preprint":false},{"year":1988,"finding":"Molecular cloning of human ACE cDNA revealed the enzyme contains 1306 residues with a signal peptide, a C-terminal membrane anchor, and two large homologous domains arising from gene duplication, each bearing a putative zinc metallopeptidase active site (HEXXH motif). A shorter testis-specific 3.0 kb transcript was also detected.","method":"Molecular cloning and cDNA sequencing of human vascular endothelial cell ACE mRNA","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — molecular cloning with complete sequence determination, foundational structural discovery","pmids":["2849100"],"is_preprint":false},{"year":1989,"finding":"Human testicular ACE (tACE) is identical to the C-terminal half (second domain) of somatic endothelial ACE, containing only the second putative metal-binding site (His-Glu-Met-Gly-His), and is encoded by a distinct shorter mRNA with a unique 5' region generated by an alternative promoter. This established that the C-terminal domain of somatic ACE contains a functionally active catalytic site.","method":"cDNA cloning and sequencing of human testicular ACE; comparison with somatic ACE sequence","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — molecular cloning with sequence determination and functional inference confirmed by catalytic equivalence","pmids":["2554286"],"is_preprint":false},{"year":1991,"finding":"Both the N-terminal and C-terminal domains of somatic ACE are independently catalytically active and each requires zinc; both are activated by chloride and are inhibited by competitive ACE inhibitors. The two domains display different catalytic constants and different patterns of chloride activation, with the C domain hydrolyzing substrates faster than the N domain at high chloride. His-361/365 (N domain) and His-959/963 (C domain) are essential for activity (zinc binding), and Glu-362 (N domain) and Glu-960 (C domain) are essential catalytic residues.","method":"Site-directed mutagenesis of each domain's active site residues; expression in CHO cells; enzymatic assay with Hip-His-Leu and angiotensin I as substrates","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of active-site residues in both domains with functional enzyme assays, replicated findings","pmids":["1851160"],"is_preprint":false},{"year":1995,"finding":"The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), a negative regulator of hematopoietic stem cell proliferation, is a highly specific natural substrate of the N-terminal active site of ACE. The N-active site hydrolyzes AcSDKP ~50-fold faster than the C-active site (kcat/Km: 0.5 vs 0.01 µM⁻¹·s⁻¹). This was confirmed using mutant ACE proteins with a single functional domain and a domain-specific monoclonal antibody.","method":"In vitro enzymatic assay using wild-type and single-active-site mutant recombinant ACE; inhibition with domain-specific monoclonal antibody","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with purified mutant enzymes plus antibody inhibition, multiple orthogonal methods","pmids":["7876104"],"is_preprint":false},{"year":1999,"finding":"ACE isoform expression in the testis is developmentally regulated: the testicular isoform (tACE) is expressed in spermatids and spermatozoa but not in normal spermatogonia or spermatocytes, whereas in neoplastic germ cells (intratubular germ cell neoplasm, seminomas) and fetal germ cells, the somatic ACE isoform (sACE) is expressed instead, suggesting that neoplastic germ cells recapitulate a fetal pattern of ACE expression.","method":"RT-PCR on laser-captured individual cell populations; immunohistochemistry with isoform-specific antibodies on human testicular tissues","journal":"Laboratory investigation; a journal of technical methods and pathology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization by laser-capture microdissection and isoform-specific immunohistochemistry with functional implication for developmental regulation","pmids":["10576213"],"is_preprint":false},{"year":2000,"finding":"ACE2, the first human homologue of ACE, was identified from a heart failure ventricle cDNA library. ACE2 contains a single metalloprotease active site and functions as a carboxypeptidase that cleaves the C-terminal leucine from angiotensin I to generate angiotensin 1-9, and also cleaves des-Arg bradykinin and neurotensin, but not bradykinin itself. ACE2 is not inhibited by lisinopril or captopril, distinguishing it enzymatically from ACE. ACE generates angiotensin II from angiotensin 1-9 in vitro and in cardiomyocyte culture. ACE2 protein is predominantly found in coronary and intrarenal vascular endothelium and renal tubular epithelium.","method":"cDNA cloning; recombinant protein expression; enzymatic assay with angiotensin peptides; immunohistochemistry","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 — molecular cloning plus in vitro enzymatic characterization with multiple substrates and inhibitor testing","pmids":["10969042"],"is_preprint":false},{"year":2000,"finding":"A human ACE homolog (ACEH/ACE2) with 40% identity and 61% similarity to human ACE was identified. It contains a single HEXXH zinc-binding domain and functions exclusively as a carboxypeptidase, cleaving single residues from angiotensin I and angiotensin II but not bradykinin or Hip-His-Leu. ACEH activity is inhibited by EDTA but not by captopril, lisinopril, or enalaprilat. Active ACEH is secreted from cells by cleavage N-terminal to the transmembrane domain.","method":"cDNA cloning; heterologous expression in CHO cells; enzymatic assay with multiple substrates; inhibitor testing","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — recombinant protein expression with systematic substrate and inhibitor profiling","pmids":["10924499"],"is_preprint":false},{"year":2001,"finding":"Purified ACE degrades amyloid beta-peptide Aβ(1-40) by cleaving at the Asp7-Ser8 bond, generating Aβ(1-7) and Aβ(8-40), fragments with reduced aggregation and cytotoxicity. ACE also inhibits Aβ aggregation and fibril formation in a dose-dependent, lisinopril-inhibitable manner, and reduces Aβ deposition and Aβ-induced PC12 cytotoxicity in vitro.","method":"In vitro enzymatic assay; reverse-phase HPLC; amino acid sequencing; MALDI-TOF/MS; electron microscopy; cytotoxicity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (HPLC, MS, EM, sequencing) establishing cleavage site; captopril inhibition confirms ACE specificity","pmids":["11604391"],"is_preprint":false},{"year":2002,"finding":"ACE inhibitors at nanomolar concentrations directly activate the bradykinin B1 receptor independently of ACE and in the absence of peptide ligands. This activation is mediated by the HEXXH zinc-binding motif (residues 195–199) in the B1 receptor's extracellular domain; site-directed mutagenesis of H195 to alanine abolished activation by ACE inhibitors but not by the peptide ligand. ACE inhibitor-induced B1 activation elevates intracellular calcium and releases NO from cultured cells.","method":"Cell-based calcium signaling assay; NO measurement; site-directed mutagenesis of B1 receptor H195; peptide competition experiments","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis of receptor motif with functional readouts (calcium, NO), but mechanism describes ACE inhibitor action on B1 receptor rather than ACE itself","pmids":["12489793"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of human testicular ACE (tACE) in complex with lisinopril at 2.0 Å resolution revealed that ACE bears little structural similarity to carboxypeptidase A despite prior mechanistic assumptions, but instead resembles neurolysin and Pyrococcus furiosus carboxypeptidase. The structure shows lisinopril coordinating the active-site zinc and forming hydrogen bonds with key residues, explaining high-affinity inhibition and providing a template for domain-selective inhibitor design.","method":"X-ray crystallography at 2.0 Å resolution of human tACE-lisinopril complex","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with inhibitor bound, foundational structural determination","pmids":["12540854"],"is_preprint":false},{"year":2004,"finding":"Kinetic characterization of full-length human ACE, its separate N- and C-domains, ACE2, and neprilysin (NEP) showed: (1) Angiotensin I is effectively cleaved by NEP (kcat/Km 6.2×10⁵ M⁻¹s⁻¹) but is a poor substrate for ACE2 (kcat/Km 3.3×10⁴ M⁻¹s⁻¹); (2) Angiotensin II is cleaved efficiently by ACE2 to Ang(1-7) (kcat/Km 2.2×10⁶ M⁻¹s⁻¹); (3) Angiotensin(1-7) is cleaved with similar efficiency by both N- and C-domains of ACE; (4) The two active sites of ACE exhibit negative cooperativity when Ang I or Ang(1-7) is substrate; (5) ACE inhibitors do not inhibit ACE2.","method":"In vitro enzymatic kinetics using active-site-titrated enzyme preparations and fluorogenic substrates; inhibitor testing","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — rigorous kinetic characterization with active-site-titrated purified enzymes, multiple substrates and inhibitors","pmids":["15283675"],"is_preprint":false},{"year":2004,"finding":"In mice with 1, 2, or 3 genomic copies of the ACE gene, higher ACE gene dosage (3-copy mice) conferred resistance to high-fat diet-induced weight gain and increased peri-epididymal adipose tissue independently of angiotensin II AT1 receptor signaling. Mass spectrometry identified ACE substrates in adipose tissue including peptides (LVVYPWTQRY, VVYPWTQRY) that inhibited protein kinase C phosphorylation in vitro, suggesting ACE influences body weight via generation of oligopeptides that modulate adipose tissue enzymes.","method":"ACE gene copy number mouse model; high-fat diet metabolic phenotyping; AT1 blocker treatment; affinity-based substrate isolation with catalytically inactive EP24.15; LC-ESI-MS/MS peptide identification; in vitro PKC assay","journal":"Physiological genomics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in vivo combined with mass spectrometry substrate identification and in vitro kinase assay; single study","pmids":["15522949"],"is_preprint":false},{"year":2005,"finding":"Cellular ACE expressed in human neuroblastoma cells promotes degradation of naturally secreted Aβ40 and Aβ42. Both N- and C-terminal active sites contribute to Aβ clearance, as an ACE construct bearing inactivating mutations in each catalytic domain had no effect on Aβ levels. Pharmacological inhibition of ACE with captopril promoted accumulation of cell-derived Aβ in media, demonstrating that ACE activity is required for Aβ degradation in living cells.","method":"Cloning of ACE from human neuroblastoma cells; site-directed mutagenesis of both active sites; Aβ accumulation assay in Aβ precursor protein-expressing cells; captopril treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — active-site mutagenesis combined with cell-based functional assay and pharmacological inhibition, two orthogonal approaches","pmids":["16154999"],"is_preprint":false},{"year":2008,"finding":"ACE enzymatic activity is modulated by its physical interaction with the kinin B2 receptor. Co-expression of somatic ACE with the kinin B2 receptor in CHO cells increased ACE catalytic activity, and this effect was blocked by the B2 receptor antagonist icatibant. Endothelial cells from B2 receptor knockout mice showed decreased ACE activity compared to wild-type cells, confirming the interaction in a physiological context.","method":"Co-expression in CHO cells; fluorescent substrate-based ACE activity assay; B2 receptor antagonist pharmacology; endothelial cells from B2 receptor KO mice","journal":"Hypertension (Dallas, Tex. : 1979)","confidence":"Medium","confidence_rationale":"Tier 2 — functional interaction demonstrated in both heterologous system and primary KO cells with pharmacological validation; no direct structural evidence of heterodimerization mechanism","pmids":["18212275"],"is_preprint":false},{"year":2009,"finding":"ACE activities (both ACE1 and ACE2) are present in porcine ocular tissues including vitreous body, retina, and ciliary body. ACE1 activity was markedly higher in ciliary body than retina, while ACE2 activities were comparable across tissues. ACE-inhibitory tripeptides (Ile-Pro-Pro, Val-Pro-Pro, Leu-Pro-Pro) inhibited ACE1 at ~1/1000th the concentration required to inhibit ACE2, demonstrating distinct pharmacological profiles for the two enzymes in ocular tissue.","method":"Fluorometric enzymatic activity assays on porcine ocular tissue fractions; inhibitor concentration-response studies","journal":"Journal of ocular pharmacology and therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — direct enzymatic activity measurement in tissue fractions; demonstrates ACE1/ACE2 differential localization and pharmacology in eye","pmids":["19232015"],"is_preprint":false},{"year":2014,"finding":"Homocysteine (Hcy) metabolites (Hcy-S-S-Hcy and Hcy thiolactone) directly homocysteinylate ACE protein via covalent modification of amino and/or sulfhydryl moieties, resulting in enhanced ACE enzymatic activity. In vitro exposure of purified ACE to these metabolites produced homocysteinylated ACE and increased ACE activity. In isolated coronary and mesenteric arteries exposed to Hcy metabolites or incubated with methionine, ACE activity was similarly enhanced, promoting angiotensin II–NADPH oxidase–superoxide-mediated endothelial dysfunction.","method":"In vitro incubation of purified ACE with Hcy metabolites; activity assay; isolated artery vascular function studies; NADPH oxidase inhibitor and AT1 receptor blocker pharmacology","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct chemical modification of purified ACE demonstrated with functional consequences in isolated tissue; single study","pmids":["25416191"],"is_preprint":false},{"year":2016,"finding":"In C. elegans, reducing activity of acn-1 (the C. elegans ACE homolog) extended mean lifespan, delayed age-related degeneration, and increased stress resistance. The lifespan extension by captopril (an ACE inhibitor) required acn-1 and could not further extend lifespan of acn-1-reduced animals, placing captopril and acn-1 in the same pathway. The ACE/acn-1 longevity pathway is additive with caloric restriction and mitochondrial insufficiency, does not require sir-2.1, hsf-1, or rict-1, but requires daf-16 (FOXO transcription factor).","method":"C. elegans genetic epistasis analysis; RNAi knockdown; pharmacological treatment with captopril; lifespan assay; stress resistance assay; double mutant analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in model organism with multiple pathway components tested; orthologous mechanism in C. elegans ACE homolog","pmids":["26918946"],"is_preprint":false},{"year":2019,"finding":"Myeloid-specific overexpression of ACE (in ACE10 mice) paradoxically reduced atherosclerotic plaque formation in ApoE-deficient mice fed an atherogenic diet, demonstrating that enhanced macrophage ACE expression is protective against atherosclerosis. Bone marrow transplantation experiments confirmed the effect was hematopoietic cell-autonomous: recipients of ACE10 bone marrow had significantly reduced lesion areas, while ACE-deficient bone marrow had no impact.","method":"Transgenic mouse model (ACE10 myeloid ACE overexpression) crossed with ApoE-/- mice; bone marrow transplantation; atherogenic diet; plaque area quantification","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — bone marrow transplantation establishes myeloid cell-autonomy; in vivo mouse model with genetic and cellular evidence; single study","pmids":["31615657"],"is_preprint":false},{"year":2022,"finding":"Radiation exposure increased ACE activity specifically in lung immune cells (myeloid cells) and promoted generation of reactive oxygen species (ROS) via NADPH oxidase 2 in human monocytes. ACE inhibition with lisinopril blocked radiation-induced ACE activity increases, ROS generation, and reduced ACE-expressing CD11b+ myeloid cell frequency in the lung. In vitro, radiation-induced ROS was blocked by inhibition of either NADPH oxidase 2 or the AT1 receptor, placing ACE upstream of the AT1/NADPH oxidase 2/ROS axis.","method":"Rat partial body irradiation and fractionated radiotherapy models; flow cytometry; in vitro human monocyte radiation experiments; NADPH oxidase inhibitor; AT1 receptor blocker; lisinopril treatment; BAL fluid cytokine analysis","journal":"International journal of radiation oncology, biology, physics","confidence":"Medium","confidence_rationale":"Tier 2 — pathway position established by pharmacological inhibition at multiple points in both in vivo and in vitro systems; single study","pmids":["35093482"],"is_preprint":false},{"year":2023,"finding":"ACE (angiotensin-converting enzyme) defines a subset of granuloma macrophages that are nonpermissive for intracellular Salmonella Typhimurium. ACE+ macrophages in infected mouse spleens are functionally distinct from ACE- macrophage populations; their abundance anticorrelates with tissue bacterial burden. TNF neutralization preferentially depleted ACE+ macrophages, linking TNF signaling to maintenance of this antimicrobial macrophage population.","method":"Single-cell RNA sequencing; flow cytometry sorting; S. Typhimurium infection mouse model; TNF neutralization experiment; spatial localization analysis","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 — scRNA-seq identity with functional correlation to bacterial burden; TNF neutralization experiment; single study without direct ACE enzymatic mechanism","pmids":["36608122"],"is_preprint":false}],"current_model":"ACE (angiotensin-converting enzyme, EC 3.4.15.1) is a membrane-bound zinc dipeptidyl carboxypeptidase with two independently catalytically active domains (N and C) arising from gene duplication; the C-domain preferentially hydrolyzes angiotensin I to angiotensin II and bradykinin to inactive fragments (both requiring zinc, chloride activation, and a catalytic Glu residue), while the N-domain has high selectivity for the hemoregulatory peptide AcSDKP; both domains contribute to Aβ degradation in cells; the enzyme's activity is enhanced by covalent homocysteinylation and by heterodimerization with the kinin B2 receptor; myeloid ACE overexpression reduces atherosclerosis and defines an antimicrobial macrophage state, while the C. elegans ortholog (acn-1) regulates aging through a daf-16-dependent pathway distinct from caloric restriction and mitochondrial pathways."},"narrative":{"teleology":[{"year":1970,"claim":"Establishing ACE's core enzymatic identity as a dipeptidyl carboxypeptidase resolved how angiotensin I is activated and bradykinin inactivated in a single catalytic step.","evidence":"In vitro enzymatic assay with purified enzyme measuring C-terminal dipeptide release","pmids":["4322742"],"confidence":"High","gaps":["Structural basis of substrate recognition unknown","Number and independence of catalytic sites not yet established"]},{"year":1984,"claim":"Demonstration that ACE also cleaves neuropeptides (substance P, neurotensin) in a chloride-dependent manner broadened its substrate repertoire beyond the renin–angiotensin system and identified an essential active-site arginine residue.","evidence":"In vitro enzymatic assay with purified human ACE; HPLC product analysis; chemical modification of arginine","pmids":["6208535"],"confidence":"High","gaps":["No three-dimensional structure to explain chloride activation mechanism","Physiological significance of neuropeptide cleavage not demonstrated in vivo"]},{"year":1988,"claim":"Cloning of full-length somatic ACE cDNA revealed the two-domain architecture arising from gene duplication, each carrying an HEXXH zinc-binding motif, fundamentally reframing ACE as a tandem metallopeptidase.","evidence":"cDNA cloning and sequencing from human vascular endothelial cells","pmids":["2849100"],"confidence":"High","gaps":["Catalytic independence of the two domains not yet proven","Whether the testis-specific transcript encodes a single-domain enzyme unclear"]},{"year":1989,"claim":"Cloning of testicular ACE showed it corresponds to the C-domain alone, transcribed from an alternative promoter, proving the C-domain is independently catalytically sufficient.","evidence":"cDNA cloning and sequencing of human testicular ACE; sequence comparison with somatic isoform","pmids":["2554286"],"confidence":"High","gaps":["Functional role of tACE in fertilization not established","Substrate preferences of isolated C-domain vs. full-length enzyme unknown"]},{"year":1991,"claim":"Site-directed mutagenesis demonstrated that both N- and C-domains are independently active, each requiring its own zinc-binding histidines and catalytic glutamate, and that the two domains differ in chloride sensitivity and kinetic parameters.","evidence":"Site-directed mutagenesis of active-site residues in each domain; expression in CHO cells; enzymatic assay","pmids":["1851160"],"confidence":"High","gaps":["Structural basis for differential chloride activation not resolved","Whether negative cooperativity between domains occurs with physiological substrates unknown"]},{"year":1995,"claim":"Identifying AcSDKP as a highly N-domain-selective substrate established the first clear functional distinction between the two active sites, linking the N-domain specifically to hematopoietic stem cell regulation.","evidence":"In vitro kinetic assay using wild-type and single-active-site mutant ACE; domain-specific antibody inhibition","pmids":["7876104"],"confidence":"High","gaps":["In vivo significance of N-domain AcSDKP hydrolysis not directly tested","Whether other N-domain-selective substrates exist is unknown"]},{"year":2001,"claim":"Showing that ACE degrades amyloid-β peptide at a defined cleavage site and inhibits Aβ aggregation expanded ACE's roles to neurodegeneration-relevant biology.","evidence":"In vitro cleavage with purified ACE; HPLC, MALDI-TOF/MS product identification; EM fibril assay; cytotoxicity assay","pmids":["11604391"],"confidence":"High","gaps":["In vivo relevance in brain parenchyma not established","Relative contribution of N- vs. C-domain to Aβ degradation unknown at this point"]},{"year":2003,"claim":"The 2.0 Å crystal structure of tACE–lisinopril complex revealed an unexpected fold related to neurolysin rather than carboxypeptidase A, providing the structural basis for inhibitor binding and rational domain-selective inhibitor design.","evidence":"X-ray crystallography at 2.0 Å resolution of human tACE in complex with lisinopril","pmids":["12540854"],"confidence":"High","gaps":["N-domain crystal structure not yet determined","Structural explanation for negative cooperativity between domains still missing"]},{"year":2004,"claim":"Comprehensive kinetic profiling of both ACE domains, ACE2, and neprilysin with angiotensin peptides established quantitative substrate preferences and demonstrated negative cooperativity between the two ACE active sites, clarifying the enzyme's role in the angiotensin cascade relative to ACE2.","evidence":"In vitro kinetics with active-site-titrated purified enzymes; fluorogenic substrate assays","pmids":["15283675"],"confidence":"High","gaps":["Molecular mechanism of negative cooperativity not structurally defined","In vivo contributions of each domain to angiotensin processing not separated"]},{"year":2005,"claim":"Demonstrating that both ACE domains contribute to Aβ degradation in living cells, and that pharmacological ACE inhibition causes Aβ accumulation, established a cell-biological context for ACE's amyloidolytic activity.","evidence":"Active-site mutagenesis; Aβ accumulation assay in neuroblastoma cells expressing APP; captopril treatment","pmids":["16154999"],"confidence":"High","gaps":["No in vivo brain model confirming ACE-dependent Aβ clearance","Relative importance of ACE vs. other Aβ-degrading enzymes not quantified"]},{"year":2008,"claim":"Discovery that the bradykinin B2 receptor physically interacts with ACE and enhances its catalytic activity introduced receptor-mediated allosteric regulation of ACE, validated by B2 receptor knockout endothelial cells.","evidence":"Co-expression in CHO cells; fluorescent ACE activity assay; B2 receptor antagonist; B2 receptor KO mouse endothelial cells","pmids":["18212275"],"confidence":"Medium","gaps":["No direct structural evidence of ACE–B2 receptor complex","Stoichiometry and binding interface unknown","Not independently replicated"]},{"year":2014,"claim":"Covalent homocysteinylation of ACE by homocysteine metabolites was shown to enhance ACE activity and promote angiotensin II–NADPH oxidase–superoxide-mediated endothelial dysfunction, providing a molecular link between hyperhomocysteinemia and vascular disease.","evidence":"In vitro modification of purified ACE with Hcy metabolites; isolated artery vascular function studies with pharmacological inhibitors","pmids":["25416191"],"confidence":"Medium","gaps":["Specific modified residues not identified","In vivo demonstration of homocysteinylated ACE in hyperhomocysteinemia not provided","Single study without independent replication"]},{"year":2016,"claim":"Genetic epistasis in C. elegans placed the ACE ortholog acn-1 in a daf-16/FOXO-dependent longevity pathway distinct from caloric restriction and mitochondrial insufficiency, extending ACE biology to aging regulation.","evidence":"C. elegans RNAi; captopril treatment; lifespan assay; double mutant epistasis analysis","pmids":["26918946"],"confidence":"Medium","gaps":["Whether mammalian ACE similarly regulates lifespan is untested","Substrate(s) of acn-1 mediating longevity are unidentified","Catalytic vs. non-catalytic roles of acn-1 not distinguished"]},{"year":2019,"claim":"Myeloid-specific ACE overexpression was shown to be atheroprotective in ApoE-deficient mice through bone marrow transplantation, establishing a cell-autonomous role for macrophage ACE in limiting atherosclerosis.","evidence":"ACE10 transgenic mice crossed with ApoE−/−; bone marrow transplantation; atherogenic diet; plaque quantification","pmids":["31615657"],"confidence":"Medium","gaps":["Downstream effector peptides or substrates in macrophages not identified","Whether N-domain, C-domain, or both mediate the atheroprotective effect is unknown","Single study without independent replication"]},{"year":2023,"claim":"Single-cell transcriptomics identified ACE as a marker of a distinct antimicrobial macrophage subset in granulomas that restricts intracellular Salmonella, with TNF signaling maintaining this population, linking ACE to innate immune defense.","evidence":"scRNA-seq; flow cytometry; S. Typhimurium mouse infection model; TNF neutralization","pmids":["36608122"],"confidence":"Medium","gaps":["Whether ACE enzymatic activity is required for the antimicrobial phenotype is untested","Mechanism by which ACE+ macrophages restrict bacteria is unknown","Not replicated in human infection settings"]},{"year":null,"claim":"Key unresolved questions include the structural basis of inter-domain negative cooperativity in full-length somatic ACE, the identity of ACE substrates mediating macrophage antimicrobial and atheroprotective functions, and whether ACE regulates mammalian lifespan through a FOXO-dependent pathway as suggested by the C. elegans ortholog.","evidence":"","pmids":[],"confidence":"Low","gaps":["Full-length somatic ACE crystal structure with both domains resolved is lacking","Macrophage-specific ACE substrates not identified","Mammalian aging phenotype of ACE modulation not tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,4,5,9,12]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,5,9,12,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[8,12]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,12,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,5,9,14]}],"complexes":[],"partners":["BDKRB2","AGT"],"other_free_text":[]},"mechanistic_narrative":"ACE is a membrane-bound zinc dipeptidyl carboxypeptidase that converts angiotensin I to angiotensin II and inactivates bradykinin, thereby serving as a central regulator of the renin–angiotensin and kallikrein–kinin systems [PMID:4322742, PMID:15283675]. The somatic enzyme contains two homologous catalytic domains (N and C), each bearing a zinc-coordinating HEXXH motif and requiring chloride for activation; the C-domain preferentially hydrolyzes angiotensin I, whereas the N-domain exhibits high selectivity for the hemoregulatory peptide AcSDKP, and both domains cooperate in degrading amyloid-β peptides [PMID:1851160, PMID:7876104, PMID:16154999]. A testis-specific isoform corresponding to the C-domain alone is transcribed from an alternative promoter in spermatids [PMID:2554286]. Beyond its classical vascular role, myeloid ACE expression defines an antimicrobial macrophage subset that restricts intracellular Salmonella and attenuates atherosclerosis, linking ACE to innate immune function [PMID:31615657, PMID:36608122]."},"prefetch_data":{"uniprot":{"accession":"P12821","full_name":"Angiotensin-converting enzyme","aliases":["Dipeptidyl carboxypeptidase I","Kininase II"],"length_aa":1306,"mass_kda":149.7,"function":"Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte homeostasis or synaptic plasticity (PubMed:15615692, PubMed:20826823, PubMed:2558109, PubMed:4322742, PubMed:7523412, PubMed:7683654). Composed of two similar catalytic domains, each possessing a functional active site, with different selectivity for substrates (PubMed:10913258, PubMed:1320019, PubMed:1851160, PubMed:19773553, PubMed:7683654, PubMed:7876104). Plays a major role in the angiotensin-renin system that regulates blood pressure and sodium retention by the kidney by converting angiotensin I to angiotensin II, resulting in an increase of the vasoconstrictor activity of angiotensin (PubMed:11432860, PubMed:1851160, PubMed:19773553, PubMed:23056909, PubMed:4322742). Also able to inactivate bradykinin, a potent vasodilator, and therefore enhance the blood pressure response (PubMed:15615692, PubMed:2558109, PubMed:4322742, PubMed:6055465, PubMed:6270633, PubMed:7683654). Acts as a regulator of synaptic transmission by mediating cleavage of neuropeptide hormones, such as substance P, neurotensin or enkephalins (PubMed:15615692, PubMed:6208535, PubMed:6270633, PubMed:656131). Catalyzes degradation of different enkephalin neuropeptides (Met-enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Phe and possibly Met-enkephalin-Arg-Gly-Leu) (PubMed:2982830, PubMed:6270633, PubMed:656131). Acts as a regulator of synaptic plasticity in the nucleus accumbens of the brain by mediating cleavage of Met-enkephalin-Arg-Phe, a strong ligand of Mu-type opioid receptor OPRM1, into Met-enkephalin (By similarity). Met-enkephalin-Arg-Phe cleavage by ACE decreases activation of OPRM1, leading to long-term synaptic potentiation of glutamate release (By similarity). Also acts as a regulator of hematopoietic stem cell differentiation by mediating degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) (PubMed:26403559, PubMed:7876104, PubMed:8257427, PubMed:8609242). Acts as a regulator of cannabinoid signaling pathway by mediating degradation of hemopressin, an antagonist peptide of the cannabinoid receptor CNR1 (PubMed:18077343). Involved in amyloid-beta metabolism by catalyzing degradation of Amyloid-beta protein 40 and Amyloid-beta protein 42 peptides, thereby preventing plaque formation (PubMed:11604391, PubMed:16154999, PubMed:19773553). Catalyzes cleavage of cholecystokinin (maturation of Cholecystokinin-8 and Cholecystokinin-5) and Gonadoliberin-1 (both maturation and degradation) hormones (PubMed:10336644, PubMed:2983326, PubMed:7683654, PubMed:9371719). Degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by the N-terminal catalytic domain, while angiotensin I and cholecystokinin cleavage is mediated by the C-terminal catalytic region (PubMed:10336644, PubMed:19773553, PubMed:7876104) Soluble form that is released in blood plasma and other body fluids following proteolytic cleavage in the juxtamembrane stalk region Isoform produced by alternative promoter usage that is specifically expressed in spermatocytes and adult testis, and which is required for male fertility (PubMed:1651327, PubMed:1668266). In contrast to somatic isoforms, only contains one catalytic domain (PubMed:1651327, PubMed:1668266). Acts as a dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of substrates (PubMed:1668266, PubMed:24297181). The identity of substrates that are needed for male fertility is unknown (By similarity). May also have a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. The GPIase activity was reported to be essential for the egg-binding ability of the sperm (By similarity). This activity is however unclear and has been challenged by other groups, suggesting that it may be indirect (By similarity)","subcellular_location":"Cell membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/P12821/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACE","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACE","total_profiled":1310},"omim":[{"mim_id":"621420","title":"ANGIOTENSIN I-CONVERTING ENZYME, PLASMA LEVEL OF","url":"https://www.omim.org/entry/621420"},{"mim_id":"621314","title":"POMPE DISEASE, LATE-ONSET; LOPD","url":"https://www.omim.org/entry/621314"},{"mim_id":"619363","title":"ANGIOEDEMA, HEREDITARY, 6; HAE6","url":"https://www.omim.org/entry/619363"},{"mim_id":"619360","title":"ANGIOEDEMA, HEREDITARY, 4; HAE4","url":"https://www.omim.org/entry/619360"},{"mim_id":"618884","title":"PROTEINURIA, CHRONIC BENIGN; PROCHOB","url":"https://www.omim.org/entry/618884"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":249.7},{"tissue":"testis","ntpm":96.4}],"url":"https://www.proteinatlas.org/search/ACE"},"hgnc":{"alias_symbol":["ACE1","CD143"],"prev_symbol":["DCP1"]},"alphafold":{"accession":"P12821","domains":[{"cath_id":"-","chopping":"905-1050_1067-1072_1122-1216","consensus_level":"medium","plddt":93.7799,"start":905,"end":1216},{"cath_id":"1.10.287","chopping":"29-126","consensus_level":"medium","plddt":94.4413,"start":29,"end":126}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P12821","model_url":"https://alphafold.ebi.ac.uk/files/AF-P12821-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P12821-F1-predicted_aligned_error_v6.png","plddt_mean":90.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACE","jax_strain_url":"https://www.jax.org/strain/search?query=ACE"},"sequence":{"accession":"P12821","fasta_url":"https://rest.uniprot.org/uniprotkb/P12821.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P12821/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P12821"}},"corpus_meta":[{"pmid":"16815998","id":"PMC_16815998","title":"mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes.","date":"2006","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16815998","citation_count":735,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15283675","id":"PMC_15283675","title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15283675","citation_count":483,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16177138","id":"PMC_16177138","title":"A crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing.","date":"2005","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16177138","citation_count":367,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16690893","id":"PMC_16690893","title":"ACE polymorphisms.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16690893","citation_count":317,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12515382","id":"PMC_12515382","title":"The human LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and Xrnl in distinct cytoplasmic foci.","date":"2002","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12515382","citation_count":303,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3043194","id":"PMC_3043194","title":"ACE1 regulates expression of the Saccharomyces cerevisiae metallothionein gene.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3043194","citation_count":238,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24651294","id":"PMC_24651294","title":"CYP6 P450 enzymes and ACE-1 duplication produce extreme and multiple insecticide resistance in the malaria mosquito Anopheles gambiae.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24651294","citation_count":235,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15731006","id":"PMC_15731006","title":"The translational regulator CPEB1 provides a link between dcp1 bodies and stress granules.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15731006","citation_count":233,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17158604","id":"PMC_17158604","title":"Arabidopsis DCP2, DCP1, and VARICOSE form a decapping complex required for postembryonic development.","date":"2006","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/17158604","citation_count":220,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25148386","id":"PMC_25148386","title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.","date":"2014","source":"The Cochrane database of systematic reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25148386","citation_count":167,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12676162","id":"PMC_12676162","title":"The angiotensin converting enzyme (ACE).","date":"2003","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12676162","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12032091","id":"PMC_12032091","title":"The DEAD box protein Dhh1 stimulates the decapping enzyme Dcp1.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12032091","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23142987","id":"PMC_23142987","title":"A direct interaction between DCP1 and XRN1 couples mRNA decapping to 5' exonucleolytic degradation.","date":"2012","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23142987","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32333398","id":"PMC_32333398","title":"A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32333398","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9068723","id":"PMC_9068723","title":"Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.","date":"1997","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9068723","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18280239","id":"PMC_18280239","title":"Structural basis of dcp2 recognition and activation by dcp1.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18280239","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6282189","id":"PMC_6282189","title":"Angiotensin converting enzyme (ACE) inhibitors.","date":"1982","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/6282189","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17993616","id":"PMC_17993616","title":"Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17993616","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2068093","id":"PMC_2068093","title":"A copper-thiolate polynuclear cluster in the ACE1 transcription factor.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2068093","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12767053","id":"PMC_12767053","title":"Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12767053","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19911001","id":"PMC_19911001","title":"Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.","date":"2009","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/19911001","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22407295","id":"PMC_22407295","title":"Dehydration stress activates Arabidopsis MPK6 to signal DCP1 phosphorylation.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22407295","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1497404","id":"PMC_1497404","title":"Cough and ACE inhibitors.","date":"1992","source":"Archives of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1497404","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34728179","id":"PMC_34728179","title":"Angiotensin converting enzyme (ACE).","date":"2021","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34728179","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14662338","id":"PMC_14662338","title":"Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells.","date":"2003","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14662338","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2664778","id":"PMC_2664778","title":"Cooperative activation of a eukaryotic transcription factor: interaction between Cu(I) and yeast ACE1 protein.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2664778","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3023783","id":"PMC_3023783","title":"Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.","date":"1986","source":"Medical toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/3023783","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33676010","id":"PMC_33676010","title":"Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients.","date":"2021","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33676010","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10624863","id":"PMC_10624863","title":"Screening of Zulu medicinal plants for angiotensin converting enzyme (ACE) inhibitors.","date":"1999","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10624863","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19793108","id":"PMC_19793108","title":"Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors.","date":"2009","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19793108","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1536695","id":"PMC_1536695","title":"Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.","date":"1992","source":"Drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/1536695","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10620209","id":"PMC_10620209","title":"ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10620209","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10944120","id":"PMC_10944120","title":"The eukaryotic mRNA decapping protein Dcp1 interacts physically and functionally with the eIF4F translation initiation complex.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10944120","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29142718","id":"PMC_29142718","title":"Heterologous expression of the avirulence gene ACE1 from the fungal rice pathogen Magnaporthe oryzae.","date":"2015","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/29142718","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1691409","id":"PMC_1691409","title":"Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.","date":"1990","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/1691409","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17923697","id":"PMC_17923697","title":"A divergent Sm fold in EDC3 proteins mediates DCP1 binding and P-body targeting.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17923697","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31835086","id":"PMC_31835086","title":"ACE inhibitor-mediated angioedema.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31835086","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16278453","id":"PMC_16278453","title":"Independent metalloregulation of Ace1 and Mac1 in Saccharomyces cerevisiae.","date":"2005","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/16278453","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17142568","id":"PMC_17142568","title":"Expression of Magnaporthe grisea avirulence gene ACE1 is connected to the initiation of appressorium-mediated penetration.","date":"2006","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/17142568","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16207815","id":"PMC_16207815","title":"Caenorhabditis elegans decapping proteins: localization and functional analysis of Dcp1, Dcp2, and DcpS during embryogenesis.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16207815","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8462229","id":"PMC_8462229","title":"Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.","date":"1993","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/8462229","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19232015","id":"PMC_19232015","title":"Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues.","date":"2009","source":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19232015","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22282502","id":"PMC_22282502","title":"Angiotensin-converting enzyme (CD143) specifies emerging lympho-hematopoietic progenitors in the human embryo.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22282502","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15492809","id":"PMC_15492809","title":"The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15492809","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2088504","id":"PMC_2088504","title":"The DNA and Cu binding functions of ACE1 are interdigitated within a single domain.","date":"1990","source":"The New biologist","url":"https://pubmed.ncbi.nlm.nih.gov/2088504","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17504229","id":"PMC_17504229","title":"Demystifying the ACE polymorphism: from genetics to biology.","date":"2007","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/17504229","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19900550","id":"PMC_19900550","title":"RNAi of ace1 and ace2 in Blattella germanica reveals their differential contribution to acetylcholinesterase activity and sensitivity to insecticides.","date":"2009","source":"Insect biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19900550","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37533188","id":"PMC_37533188","title":"Bifidobacterium adolescentis orchestrates CD143+ cancer-associated fibroblasts to suppress colorectal tumorigenesis by Wnt signaling-regulated GAS1.","date":"2023","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37533188","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8509391","id":"PMC_8509391","title":"Regulation of metallothionein genes by the ACE1 and AMT1 transcription factors.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8509391","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33476334","id":"PMC_33476334","title":"Resistance to pirimiphos-methyl in West African Anopheles is spreading via duplication and introgression of the Ace1 locus.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33476334","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14504631","id":"PMC_14504631","title":"Association of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with essential hypertension.","date":"2003","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/14504631","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26918946","id":"PMC_26918946","title":"Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26918946","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27694842","id":"PMC_27694842","title":"Structural basis of mRNA-cap recognition by Dcp1-Dcp2.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27694842","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27183195","id":"PMC_27183195","title":"Structure of the Dcp2-Dcp1 mRNA-decapping complex in the activated conformation.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27183195","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19812249","id":"PMC_19812249","title":"Dcp1-bodies in mouse oocytes.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19812249","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27694841","id":"PMC_27694841","title":"Structure of the active form of Dcp1-Dcp2 decapping enzyme bound to m7GDP and its Edc3 activator.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27694841","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11504737","id":"PMC_11504737","title":"Haa1, a protein homologous to the copper-regulated transcription factor Ace1, is a novel transcriptional activator.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11504737","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9739417","id":"PMC_9739417","title":"Effect of angiotensin converting enzyme (ACE) and angiotensins on human sperm functions.","date":"1998","source":"Andrologia","url":"https://pubmed.ncbi.nlm.nih.gov/9739417","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15522949","id":"PMC_15522949","title":"ACE gene titration in mice uncovers a new mechanism for ACE on the control of body weight.","date":"2004","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15522949","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9272166","id":"PMC_9272166","title":"Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography.","date":"1997","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9272166","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15106838","id":"PMC_15106838","title":"APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease.","date":"2004","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/15106838","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15147752","id":"PMC_15147752","title":"Zinc-metalloproteases in insects: ACE and ECE.","date":"2004","source":"Insect biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15147752","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12489793","id":"PMC_12489793","title":"Activation of bradykinin B1 receptor by ACE inhibitors.","date":"2002","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12489793","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29559651","id":"PMC_29559651","title":"Structure of the activated Edc1-Dcp1-Dcp2-Edc3 mRNA decapping complex with substrate analog poised for catalysis.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29559651","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34947975","id":"PMC_34947975","title":"Two Opposing Functions of Angiotensin-Converting Enzyme (ACE) That Links Hypertension, Dementia, and Aging.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34947975","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10576213","id":"PMC_10576213","title":"Angiotensin-converting enzyme (CD143) in neoplastic germ cells.","date":"1999","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10576213","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8513428","id":"PMC_8513428","title":"Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors.","date":"1993","source":"The Canadian journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/8513428","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18212275","id":"PMC_18212275","title":"ACE activity is modulated by kinin B2 receptor.","date":"2008","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/18212275","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1505143","id":"PMC_1505143","title":"Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.","date":"1992","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/1505143","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35093482","id":"PMC_35093482","title":"Pharmacologic ACE-Inhibition Mitigates Radiation-Induced Pneumonitis by Suppressing ACE-Expressing Lung Myeloid Cells.","date":"2022","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/35093482","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29357900","id":"PMC_29357900","title":"Insecticide resistance and target site mutations (G119S ace-1 and L1014F kdr) of Culex pipiens in Morocco.","date":"2018","source":"Parasites & vectors","url":"https://pubmed.ncbi.nlm.nih.gov/29357900","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2043220","id":"PMC_2043220","title":"Metabolic effects of ACE inhibitors.","date":"1991","source":"Journal of internal medicine. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/2043220","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25339350","id":"PMC_25339350","title":"Diffuse decapping enzyme DCP2 accumulates in DCP1 foci under heat stress in Arabidopsis thaliana.","date":"2014","source":"Plant & cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25339350","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1324185","id":"PMC_1324185","title":"ACE-inhibitors and atherosclerosis.","date":"1992","source":"European journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/1324185","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21441775","id":"PMC_21441775","title":"The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21441775","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15781381","id":"PMC_15781381","title":"[Angiotensin I-converting enzyme (ACE) for sarcoidosis diagnosis].","date":"2005","source":"Pathologie-biologie","url":"https://pubmed.ncbi.nlm.nih.gov/15781381","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16329762","id":"PMC_16329762","title":"The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae.","date":"2005","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16329762","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21053061","id":"PMC_21053061","title":"Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart.","date":"2011","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/21053061","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30364987","id":"PMC_30364987","title":"Human MARF1 is an endoribonuclease that interacts with the DCP1:2 decapping complex and degrades target mRNAs.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30364987","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2556234","id":"PMC_2556234","title":"Enzymes in sarcoidosis. Angiotensin-converting-enzyme (ACE).","date":"1989","source":"Clinics in laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2556234","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15671491","id":"PMC_15671491","title":"Decapping reaction of mRNA requires Dcp1 in fission yeast: its characterization in different species from yeast to human.","date":"2004","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15671491","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6315257","id":"PMC_6315257","title":"Angiotensin-converting enzyme (ACE) in sepsis.","date":"1983","source":"Circulatory shock","url":"https://pubmed.ncbi.nlm.nih.gov/6315257","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9581523","id":"PMC_9581523","title":"Angiotensin converting enzyme (ACE) inhibitors from Jasminum azoricum and Jasminum grandiflorum.","date":"1998","source":"Planta medica","url":"https://pubmed.ncbi.nlm.nih.gov/9581523","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12148094","id":"PMC_12148094","title":"ACE genotype and ACE inhibitor response in kidney disease: a perspective.","date":"2002","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/12148094","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22489048","id":"PMC_22489048","title":"Extensive Ace2 duplication and multiple mutations on Ace1 and Ace2 are related with high level of organophosphates resistance in Aphis gossypii.","date":"2012","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22489048","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20692300","id":"PMC_20692300","title":"Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors.","date":"2010","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/20692300","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35396835","id":"PMC_35396835","title":"Dysregulation of ACE-1 in Normal Aging and the Early Stages of Alzheimer's Disease.","date":"2022","source":"The journals of gerontology. Series A, Biological sciences and medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35396835","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8343519","id":"PMC_8343519","title":"Distinct metal binding configurations in ACE1.","date":"1993","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8343519","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9402467","id":"PMC_9402467","title":"From kinetics to dynamics: are there differences between ACE inhibitors?","date":"1997","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/9402467","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17550823","id":"PMC_17550823","title":"Molecular cloning and characterization of the complete acetylcholinesterase gene (Ace1) from the mosquito Aedes aegypti with implications for comparative genome analysis.","date":"2007","source":"Insect biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17550823","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27628189","id":"PMC_27628189","title":"Bradykinin -induced vasodilatation: Role of age, ACE1-inhibitory peptide, mas- and bradykinin receptors.","date":"2016","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/27628189","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36608122","id":"PMC_36608122","title":"Single-cell profiling identifies ACE+ granuloma macrophages as a nonpermissive niche for intracellular bacteria during persistent Salmonella infection.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36608122","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35245599","id":"PMC_35245599","title":"Role and Interaction Between ACE1, ACE2 and Their Related Genes in Cardiovascular Disorders.","date":"2022","source":"Current problems in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35245599","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33089502","id":"PMC_33089502","title":"Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.","date":"2020","source":"The Cochrane database of systematic reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33089502","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31615657","id":"PMC_31615657","title":"Overexpression of myeloid angiotensin-converting enzyme (ACE) reduces atherosclerosis.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31615657","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34774774","id":"PMC_34774774","title":"Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients.","date":"2021","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34774774","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25416191","id":"PMC_25416191","title":"Role of homocysteinylation of ACE in endothelial dysfunction of arteries.","date":"2014","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25416191","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20402757","id":"PMC_20402757","title":"The I/D polymorphism of the ACE1 gene is not associated with ischaemic stroke in Spanish individuals.","date":"2010","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20402757","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28587581","id":"PMC_28587581","title":"ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.","date":"2017","source":"Journal of cardiovascular pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28587581","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2193808","id":"PMC_2193808","title":"Haemodynamic effects of ACE inhibitors.","date":"1990","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/2193808","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10969042","id":"PMC_10969042","title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.","date":"2000","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10969042","citation_count":2338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22412018","id":"PMC_22412018","title":"A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells.","date":"2012","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22412018","citation_count":1850,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1328889","id":"PMC_1328889","title":"Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1328889","citation_count":1796,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15326289","id":"PMC_15326289","title":"Identification and proteomic profiling of exosomes in human urine.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15326289","citation_count":1724,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10924499","id":"PMC_10924499","title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10924499","citation_count":1641,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24816252","id":"PMC_24816252","title":"An atlas of genetic influences on human blood metabolites.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24816252","citation_count":1209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18583979","id":"PMC_18583979","title":"Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18583979","citation_count":817,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21886157","id":"PMC_21886157","title":"Human metabolic individuality in biomedical and pharmaceutical research.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21886157","citation_count":801,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391210","id":"PMC_10391210","title":"Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391210","citation_count":769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2849100","id":"PMC_2849100","title":"Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2849100","citation_count":716,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12459472","id":"PMC_12459472","title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12459472","citation_count":609,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12540854","id":"PMC_12540854","title":"Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12540854","citation_count":582,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4322742","id":"PMC_4322742","title":"A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin.","date":"1970","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/4322742","citation_count":539,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6208535","id":"PMC_6208535","title":"Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase.","date":"1984","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/6208535","citation_count":459,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1338766","id":"PMC_1338766","title":"Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension.","date":"1992","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1338766","citation_count":384,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10319862","id":"PMC_10319862","title":"Sequence variation in the human angiotensin converting enzyme.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10319862","citation_count":357,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15671045","id":"PMC_15671045","title":"Myocardial infarction increases ACE2 expression in rat and humans.","date":"2005","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/15671045","citation_count":346,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1851160","id":"PMC_1851160","title":"The two homologous domains of human angiotensin I-converting enzyme are both catalytically active.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1851160","citation_count":338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15534175","id":"PMC_15534175","title":"Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls.","date":"2004","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15534175","citation_count":313,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12204859","id":"PMC_12204859","title":"Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome.","date":"2002","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12204859","citation_count":307,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11604391","id":"PMC_11604391","title":"Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11604391","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15023884","id":"PMC_15023884","title":"Renin-angiotensin system gene polymorphisms and atrial fibrillation.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15023884","citation_count":281,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7876104","id":"PMC_7876104","title":"The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7876104","citation_count":275,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2554286","id":"PMC_2554286","title":"Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2554286","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16154999","id":"PMC_16154999","title":"Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16154999","citation_count":270,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47617,"output_tokens":3139,"usd":0.094968},"stage2":{"model":"claude-opus-4-6","input_tokens":6506,"output_tokens":2944,"usd":0.159195},"total_usd":0.61333,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":61010,"output_tokens":8041,"usd":0.151822},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10206,"output_tokens":3488,"usd":0.207345}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Full-length human ACE cleaves angiotensin I to angiotensin II; the separate N- and C-domains of somatic ACE both cleave Ang I, Ang (1-7), and Ang (1-9) with similar efficiency (kcat/Km ~3.3–3.6 × 10^5 M^-1 s^-1 for Ang 1-7), and the two active sites exhibit negative cooperativity when Ang I or Ang (1-7) is the substrate. ACE inhibitors do not inhibit ACE2.\",\n      \"method\": \"In vitro kinetic assay with active-site titration using competitive tight-binding inhibitors and fluorogenic substrates; separate N- and C-domain preparations\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetics with purified enzyme domains, active-site titration, multiple substrates\",\n      \"pmids\": [\"15283675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Somatic ACE is a dual-domain integral membrane metallopeptidase (dipeptidyl carboxylase) with two active sites that have distinct substrate affinities; a single-domain germinal isoform (tACE) is expressed only in testis and is required for male fertility, as shown by mouse knockout experiments.\",\n      \"method\": \"Mouse gene knockout; comparative biochemistry of isoforms\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mouse KO with defined fertility phenotype, replicated across labs\",\n      \"pmids\": [\"12676162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ACE inhibitors (e.g., enalaprilat) at nanomolar concentrations directly activate the bradykinin B1 receptor through interaction with the Zn-binding HEXXH motif (residues 195–199) of the B1 receptor, independent of ACE enzymatic activity or peptide ligands, elevating intracellular Ca2+ and releasing NO; mutation H195A abolishes this activation.\",\n      \"method\": \"Cell-based assay with recombinant B1 receptor; site-directed mutagenesis of H195; Ca2+ measurement; NO release assay; blocking with synthetic peptide representing B1 receptor residues 192–202\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis + functional assay, single lab\",\n      \"pmids\": [\"12489793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ACE enzymatic activity is modulated by its physical interaction (heterodimerization) with the kinin B2 receptor; coexpression of B2 receptor with somatic ACE in CHO cells augments ACE catalytic activity, an effect blocked by the B2 antagonist icatibant; endothelial cells from B2 receptor knockout mice show reduced ACE activity.\",\n      \"method\": \"Fluorescent substrate assay in CHO cells coexpressing ACE and B2 receptor; pharmacological blockade with icatibant; comparison of wild-type vs. B2-KO mouse endothelial cells\",\n      \"journal\": \"Hypertension (Dallas, Tex. : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based functional assay + genetic model, single lab\",\n      \"pmids\": [\"18212275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Homocysteine metabolites (Hcy-S-S-Hcy and homocysteine thiolactone) directly homocysteinylate ACE amino- and sulfhydryl groups in vitro, enhancing ACE enzymatic activity and promoting ANG II–NADPH oxidase–superoxide-dependent endothelial dysfunction in isolated arteries.\",\n      \"method\": \"In vitro incubation of purified ACE with Hcy metabolites; enzyme activity assay; isolated vessel bioassay; NADPH oxidase and AT1 receptor inhibitor experiments\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro biochemical modification of purified ACE plus ex vivo vascular functional studies, single lab\",\n      \"pmids\": [\"25416191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ACE gene copy number in mice inversely correlates with body weight and peri-epididymal fat on a high-fat diet; using a catalytically inactive form of thimet oligopeptidase to trap ACE substrates from adipose tissue, LC-ESI-MS/MS identified oligopeptides (including LVVYPWTQRY and VVYPWTQRY) as ACE substrates that inhibit protein kinase C phosphorylation in vitro, suggesting ACE controls body weight via generation of adipose oligopeptides that inhibit oligopeptidase activity.\",\n      \"method\": \"Mouse gene titration (1, 2, or 3 ACE copies); affinity capture of substrates with inactive EP24.15; LC-ESI-MS/MS peptide identification; in vitro PKC phosphorylation assay; neurolysin activity measurement\",\n      \"journal\": \"Physiological genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model + mass spectrometry substrate identification + in vitro assay, single lab\",\n      \"pmids\": [\"15522949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In C. elegans, reducing acn-1 (ACE ortholog) activity extends mean lifespan, delays age-related degeneration, and increases stress resistance; captopril extends lifespan by inhibiting acn-1, as captopril cannot further extend lifespan in acn-1-reduced animals. The pathway requires daf-16 (FOXO) and is additive with daf-2/age-1 (insulin/IGF-1 pathway) and caloric restriction.\",\n      \"method\": \"Genetic epistasis in C. elegans; RNAi/mutant lifespan assays; double-mutant analysis with insulin pathway, caloric restriction, and mitochondrial mutants\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis across multiple genetic backgrounds, single lab\",\n      \"pmids\": [\"26918946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"ACE (kininase II) is localized to the luminal surface of pulmonary endothelial cells where it converts angiotensin I to angiotensin II and inactivates bradykinin; sepsis causes marked depletion of serum ACE activity correlating with reduced mean arterial pressure, consistent with reduced bradykinin inactivation.\",\n      \"method\": \"Serum ACE activity measurement in E. coli sepsis baboon model; correlation with hemodynamic parameters\",\n      \"journal\": \"Circulatory shock\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — in vivo activity measurement with hemodynamic correlation, single study\",\n      \"pmids\": [\"6315257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ACE (CD143) marks hematopoietic stem cells throughout human ontogeny; BB9+CD34+ umbilical cord blood cells transplanted into NOD/SCID mice engraft 10-fold more efficiently than BB9-CD34+ cells, demonstrating that ACE expression identifies functionally superior HSCs; protein microsequencing confirmed the BB9 antigen is somatic ACE.\",\n      \"method\": \"Flow cytometry; NOD/SCID xenotransplantation; protein microsequencing of immunoprecipitated BB9 antigen\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — protein identification by microsequencing + functional xenotransplantation assay\",\n      \"pmids\": [\"17993616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ACE (CD143) expression characterizes embryonic mesodermal precursors in the human para-aortic splanchnopleura responsible for definitive hematopoiesis; CD34+ACE+ fetal liver and bone marrow cells possess long-term culture-initiating cell potential and sustain multilineage engraftment in NOD/SCID mice, whereas CD34+ACE- cells do not.\",\n      \"method\": \"Cell sorting; long-term culture-initiating cell assay; NOD/SCID xenotransplantation; hematopoietic colony formation assay from splanchnopleural ACE+ cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional xenotransplantation + colony assays with sorted populations\",\n      \"pmids\": [\"22282502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Radiation-induced increases in ACE activity within lung myeloid cells (monocytes/macrophages) drive radiation pneumonitis via the ACE/AT1 receptor/NADPH oxidase 2/ROS pathway; pharmacological ACE inhibition with lisinopril suppresses ACE expression, reduces lung myeloid cell frequency, and improves survival; in vitro, radiation directly activates ACE and ROS in human monocytes, blocked by NADPH oxidase 2 or AT1 receptor inhibitors.\",\n      \"method\": \"Rat partial-body irradiation model; in vitro human monocyte irradiation; ACE activity assay; ROS measurement; NADPH oxidase 2 and AT1 receptor inhibitor experiments; flow cytometry\",\n      \"journal\": \"International journal of radiation oncology, biology, physics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model + in vitro mechanistic dissection with pharmacological inhibitors, single lab\",\n      \"pmids\": [\"35093482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ACE+ granuloma macrophages in spleen during persistent Salmonella infection are nonpermissive for intracellular bacteria; ACE+ macrophage abundance anticorrelates with tissue bacterial burden; TNF neutralization preferentially depletes ACE+ macrophages, disrupting pathogen control.\",\n      \"method\": \"Single-cell RNA sequencing; S. enterica mouse infection model; S. enterica penetration mutant; anti-TNF treatment; bacterial burden quantification\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNAseq + genetic/pharmacological perturbation in vivo, single lab\",\n      \"pmids\": [\"36608122\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACE (angiotensin-converting enzyme) is a zinc-dependent dipeptidyl carboxylase expressed as a dual-domain somatic isoform (on endothelial and immune cells) and a single-domain testicular isoform required for male fertility; it cleaves angiotensin I to the vasopressor angiotensin II and inactivates bradykinin, with the two somatic active sites showing negative cooperativity, while ACE activity is further modulated by physical interaction with the kinin B2 receptor, homocysteinylation of its active-site residues, and radiation-induced activation in myeloid cells through an AT1 receptor–NADPH oxidase–ROS pathway; beyond the renin-angiotensin system, ACE marks and functionally supports hematopoietic stem cells, shapes innate immune responses against intracellular pathogens, and influences body weight via generation of adipose oligopeptides, with ACE inhibition also extending lifespan in C. elegans through a daf-16-dependent pathway distinct from canonical longevity axes.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nMany papers in this corpus are about DCP1/DCP2 mRNA decapping complexes, GW182, LSm proteins, etc. — these are about mRNA decapping machinery, NOT the human ACE (angiotensin-converting enzyme, also known as DCP1/kininase II). However, ACE's gene symbol is also listed as DCP1 in some databases (peptidyl-dipeptidase A). I need to be careful: the DCP1 in mRNA decapping is a completely different protein (Decapping Protein 1) from ACE (Angiotensin Converting Enzyme). These are SYMBOL COLLISIONS — EXCLUDE.\n\nPapers about yeast ACE1 (copper-regulated transcription factor in S. cerevisiae) — this is a SYMBOL COLLISION with human ACE (angiotensin-converting enzyme). EXCLUDE.\n\nPapers about insect Ace1/ace-1 (acetylcholinesterase) — SYMBOL COLLISION. EXCLUDE.\n\nPapers about Magnaporthe ACE1 (fungal avirulence gene) — SYMBOL COLLISION. EXCLUDE.\n\nPapers about Arabidopsis DCP1/DCP2 — SYMBOL COLLISION. EXCLUDE.\n\nPapers about the canonical human ACE (angiotensin-converting enzyme, EC 3.4.15.1) — KEEP.\n\n**KEEP list:**\n- PMID:15283675 (Rice et al. 2004 — kinetics of ACE, ACE2, NEP)\n- PMID:16690893 (ACE polymorphisms review — mostly genetic, minimal mechanistic)\n- PMID:12676162 (Coates 2003 — ACE review with mechanistic content)\n- PMID:25148386 (ACE inhibitors vs ARBs — clinical, EXCLUDE mechanistic)\n- PMID:32333398 (Sriram 2020 — ACE1/ACE2 imbalance hypothesis — review)\n- PMID:17993616 (ACE as HSC marker — expression, minimal mechanism)\n- PMID:14662338 (ACE in dendritic cells — expression)\n- PMID:12767053 (Henriksen 2003 — ACE inhibition metabolic effects — review)\n- PMID:19911001 (Hanif 2009 — ACE inhibitor review)\n- PMID:15522949 (Heimann 2004 — ACE gene titration, body weight, peptide substrates)\n- PMID:18212275 (Sabatini 2008 — ACE activity modulated by kinin B2 receptor)\n- PMID:12489793 (Ignjatovic 2002 — ACE inhibitors activate B1 receptor)\n- PMID:25416191 (Huang 2014 — homocysteinylation of ACE)\n- PMID:35093482 (Sharma 2022 — ACE in lung myeloid cells, radiation)\n- PMID:19793108 (Huang 2009 — ACE inhibitors upregulate ACE2 in fibrosis)\n- PMID:26918946 (Kumar 2016 — ACE inhibitor extends C. elegans lifespan)\n- PMID:34947975 (Le 2021 — ACE opposing functions review)\n- PMID:36608122 (Pham 2023 — ACE+ macrophages in Salmonella)\n- PMID:31615657 (Okwan-Duodu 2019 — myeloid ACE reduces atherosclerosis)\n- PMID:10969042 (Donoghue 2000 — ACE2 discovery)\n- PMID:10924499 (Tipnis 2000 — ACE homolog ACEH)\n- PMID:2849100 (Soubrier 1988 — molecular cloning of ACE, two domains)\n- PMID:1851160 (Wei 1991 — both domains catalytically active)\n- PMID:12540854 (Natesh 2003 — crystal structure ACE-lisinopril)\n- PMID:4322742 (Yang 1970 — dipeptidyl carboxypeptidase)\n- PMID:6208535 (Skidgel 1984 — ACE cleaves substance P, neurotensin)\n- PMID:7876104 (Rousseau 1995 — AcSDKP is N-domain specific substrate)\n- PMID:11604391 (Hu 2001 — ACE degrades amyloid beta)\n- PMID:16154999 (Hemming 2005 — cellular ACE degrades Abeta)\n- PMID:2554286 (Ehlers 1989 — testicular ACE cloning)\n- PMID:10576213 (Pauls 1999 — ACE isoforms in testicular tumors)\n- PMID:66113 (ACE in neoplastic germ cells — expression)\n- PMID:22282502 (Sinka 2012 — ACE marks hematopoietic progenitors)\n- PMID:21441775 (Shen 2011 — ACE peptide network in hematopoiesis — review)\n- PMID:10620209 — renoprotection/genetics EXCLUDE (no mechanism)\n- PMID:34728179 — review, minimal mechanism\n- PMID:35396835 — ACE-1 activity in Alzheimer's brain — some mechanistic\n- PMID:35245599 — review\n- PMID:19056867 — exosomes proteomics, ACE identified but no mechanism\n- PMID:15326289 — exosomes, ACE identified\n- PMID:22412018 — BioID method paper\n- PMID:33961781 — interactome, ACE listed\n- PMID:1691409 (Fabris 1990 — tissue ACE inhibition kinetics)\n- PMID:19232015 (Luhtala 2009 — ACE1 and ACE2 activities in ocular tissues)\n- PMID:15671045 (Burrell 2005 — ACE2 increases after MI)\n- PMID:12459472 (Harmer 2002 — ACE2 expression profiling)\n- PMID:21053061 (Hanafy 2011 — ACE/ACE2 balance in inflammation)\n- PMID:20692300 (Larrinaga 2010 — ACE/ACE2 downregulated in renal tumors — expression)\n- PMID:9739417 (Köhn 1998 — ACE and angiotensins on sperm functions)\n\nNow I'll extract mechanistic discoveries from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1970,\n      \"finding\": \"ACE (angiotensin-converting enzyme) functions as a dipeptidyl carboxypeptidase that converts angiotensin I to angiotensin II and inactivates bradykinin by cleaving C-terminal dipeptides.\",\n      \"method\": \"In vitro enzymatic assay with purified enzyme\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational in vitro enzymatic characterization, replicated across decades\",\n      \"pmids\": [\"4322742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Purified human ACE cleaves substance P at Phe8-Gly9 and Gly9-Leu10 (releasing C-terminal tri- and dipeptides in ~4:1 ratio) and cleaves neurotensin at Tyr11-Ile12; hydrolysis is Cl⁻-dependent, inhibited by captopril, and requires an active-site arginine residue (modification of Arg abolishes hydrolysis of substance P, bradykinin, and Bz-Gly-Phe-Arg by 80–93%).\",\n      \"method\": \"In vitro enzymatic assay with purified ACE; HPLC analysis; chemical modification of active-site arginine\",\n      \"journal\": \"Peptides\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with chemical mutagenesis of active site, multiple substrates tested\",\n      \"pmids\": [\"6208535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Molecular cloning of human ACE cDNA revealed the enzyme contains 1306 residues with a signal peptide, a C-terminal membrane anchor, and two large homologous domains arising from gene duplication, each bearing a putative zinc metallopeptidase active site (HEXXH motif). A shorter testis-specific 3.0 kb transcript was also detected.\",\n      \"method\": \"Molecular cloning and cDNA sequencing of human vascular endothelial cell ACE mRNA\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular cloning with complete sequence determination, foundational structural discovery\",\n      \"pmids\": [\"2849100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Human testicular ACE (tACE) is identical to the C-terminal half (second domain) of somatic endothelial ACE, containing only the second putative metal-binding site (His-Glu-Met-Gly-His), and is encoded by a distinct shorter mRNA with a unique 5' region generated by an alternative promoter. This established that the C-terminal domain of somatic ACE contains a functionally active catalytic site.\",\n      \"method\": \"cDNA cloning and sequencing of human testicular ACE; comparison with somatic ACE sequence\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular cloning with sequence determination and functional inference confirmed by catalytic equivalence\",\n      \"pmids\": [\"2554286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Both the N-terminal and C-terminal domains of somatic ACE are independently catalytically active and each requires zinc; both are activated by chloride and are inhibited by competitive ACE inhibitors. The two domains display different catalytic constants and different patterns of chloride activation, with the C domain hydrolyzing substrates faster than the N domain at high chloride. His-361/365 (N domain) and His-959/963 (C domain) are essential for activity (zinc binding), and Glu-362 (N domain) and Glu-960 (C domain) are essential catalytic residues.\",\n      \"method\": \"Site-directed mutagenesis of each domain's active site residues; expression in CHO cells; enzymatic assay with Hip-His-Leu and angiotensin I as substrates\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of active-site residues in both domains with functional enzyme assays, replicated findings\",\n      \"pmids\": [\"1851160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP), a negative regulator of hematopoietic stem cell proliferation, is a highly specific natural substrate of the N-terminal active site of ACE. The N-active site hydrolyzes AcSDKP ~50-fold faster than the C-active site (kcat/Km: 0.5 vs 0.01 µM⁻¹·s⁻¹). This was confirmed using mutant ACE proteins with a single functional domain and a domain-specific monoclonal antibody.\",\n      \"method\": \"In vitro enzymatic assay using wild-type and single-active-site mutant recombinant ACE; inhibition with domain-specific monoclonal antibody\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with purified mutant enzymes plus antibody inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"7876104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ACE isoform expression in the testis is developmentally regulated: the testicular isoform (tACE) is expressed in spermatids and spermatozoa but not in normal spermatogonia or spermatocytes, whereas in neoplastic germ cells (intratubular germ cell neoplasm, seminomas) and fetal germ cells, the somatic ACE isoform (sACE) is expressed instead, suggesting that neoplastic germ cells recapitulate a fetal pattern of ACE expression.\",\n      \"method\": \"RT-PCR on laser-captured individual cell populations; immunohistochemistry with isoform-specific antibodies on human testicular tissues\",\n      \"journal\": \"Laboratory investigation; a journal of technical methods and pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by laser-capture microdissection and isoform-specific immunohistochemistry with functional implication for developmental regulation\",\n      \"pmids\": [\"10576213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ACE2, the first human homologue of ACE, was identified from a heart failure ventricle cDNA library. ACE2 contains a single metalloprotease active site and functions as a carboxypeptidase that cleaves the C-terminal leucine from angiotensin I to generate angiotensin 1-9, and also cleaves des-Arg bradykinin and neurotensin, but not bradykinin itself. ACE2 is not inhibited by lisinopril or captopril, distinguishing it enzymatically from ACE. ACE generates angiotensin II from angiotensin 1-9 in vitro and in cardiomyocyte culture. ACE2 protein is predominantly found in coronary and intrarenal vascular endothelium and renal tubular epithelium.\",\n      \"method\": \"cDNA cloning; recombinant protein expression; enzymatic assay with angiotensin peptides; immunohistochemistry\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular cloning plus in vitro enzymatic characterization with multiple substrates and inhibitor testing\",\n      \"pmids\": [\"10969042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A human ACE homolog (ACEH/ACE2) with 40% identity and 61% similarity to human ACE was identified. It contains a single HEXXH zinc-binding domain and functions exclusively as a carboxypeptidase, cleaving single residues from angiotensin I and angiotensin II but not bradykinin or Hip-His-Leu. ACEH activity is inhibited by EDTA but not by captopril, lisinopril, or enalaprilat. Active ACEH is secreted from cells by cleavage N-terminal to the transmembrane domain.\",\n      \"method\": \"cDNA cloning; heterologous expression in CHO cells; enzymatic assay with multiple substrates; inhibitor testing\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — recombinant protein expression with systematic substrate and inhibitor profiling\",\n      \"pmids\": [\"10924499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Purified ACE degrades amyloid beta-peptide Aβ(1-40) by cleaving at the Asp7-Ser8 bond, generating Aβ(1-7) and Aβ(8-40), fragments with reduced aggregation and cytotoxicity. ACE also inhibits Aβ aggregation and fibril formation in a dose-dependent, lisinopril-inhibitable manner, and reduces Aβ deposition and Aβ-induced PC12 cytotoxicity in vitro.\",\n      \"method\": \"In vitro enzymatic assay; reverse-phase HPLC; amino acid sequencing; MALDI-TOF/MS; electron microscopy; cytotoxicity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (HPLC, MS, EM, sequencing) establishing cleavage site; captopril inhibition confirms ACE specificity\",\n      \"pmids\": [\"11604391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ACE inhibitors at nanomolar concentrations directly activate the bradykinin B1 receptor independently of ACE and in the absence of peptide ligands. This activation is mediated by the HEXXH zinc-binding motif (residues 195–199) in the B1 receptor's extracellular domain; site-directed mutagenesis of H195 to alanine abolished activation by ACE inhibitors but not by the peptide ligand. ACE inhibitor-induced B1 activation elevates intracellular calcium and releases NO from cultured cells.\",\n      \"method\": \"Cell-based calcium signaling assay; NO measurement; site-directed mutagenesis of B1 receptor H195; peptide competition experiments\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of receptor motif with functional readouts (calcium, NO), but mechanism describes ACE inhibitor action on B1 receptor rather than ACE itself\",\n      \"pmids\": [\"12489793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of human testicular ACE (tACE) in complex with lisinopril at 2.0 Å resolution revealed that ACE bears little structural similarity to carboxypeptidase A despite prior mechanistic assumptions, but instead resembles neurolysin and Pyrococcus furiosus carboxypeptidase. The structure shows lisinopril coordinating the active-site zinc and forming hydrogen bonds with key residues, explaining high-affinity inhibition and providing a template for domain-selective inhibitor design.\",\n      \"method\": \"X-ray crystallography at 2.0 Å resolution of human tACE-lisinopril complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with inhibitor bound, foundational structural determination\",\n      \"pmids\": [\"12540854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Kinetic characterization of full-length human ACE, its separate N- and C-domains, ACE2, and neprilysin (NEP) showed: (1) Angiotensin I is effectively cleaved by NEP (kcat/Km 6.2×10⁵ M⁻¹s⁻¹) but is a poor substrate for ACE2 (kcat/Km 3.3×10⁴ M⁻¹s⁻¹); (2) Angiotensin II is cleaved efficiently by ACE2 to Ang(1-7) (kcat/Km 2.2×10⁶ M⁻¹s⁻¹); (3) Angiotensin(1-7) is cleaved with similar efficiency by both N- and C-domains of ACE; (4) The two active sites of ACE exhibit negative cooperativity when Ang I or Ang(1-7) is substrate; (5) ACE inhibitors do not inhibit ACE2.\",\n      \"method\": \"In vitro enzymatic kinetics using active-site-titrated enzyme preparations and fluorogenic substrates; inhibitor testing\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous kinetic characterization with active-site-titrated purified enzymes, multiple substrates and inhibitors\",\n      \"pmids\": [\"15283675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In mice with 1, 2, or 3 genomic copies of the ACE gene, higher ACE gene dosage (3-copy mice) conferred resistance to high-fat diet-induced weight gain and increased peri-epididymal adipose tissue independently of angiotensin II AT1 receptor signaling. Mass spectrometry identified ACE substrates in adipose tissue including peptides (LVVYPWTQRY, VVYPWTQRY) that inhibited protein kinase C phosphorylation in vitro, suggesting ACE influences body weight via generation of oligopeptides that modulate adipose tissue enzymes.\",\n      \"method\": \"ACE gene copy number mouse model; high-fat diet metabolic phenotyping; AT1 blocker treatment; affinity-based substrate isolation with catalytically inactive EP24.15; LC-ESI-MS/MS peptide identification; in vitro PKC assay\",\n      \"journal\": \"Physiological genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo combined with mass spectrometry substrate identification and in vitro kinase assay; single study\",\n      \"pmids\": [\"15522949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cellular ACE expressed in human neuroblastoma cells promotes degradation of naturally secreted Aβ40 and Aβ42. Both N- and C-terminal active sites contribute to Aβ clearance, as an ACE construct bearing inactivating mutations in each catalytic domain had no effect on Aβ levels. Pharmacological inhibition of ACE with captopril promoted accumulation of cell-derived Aβ in media, demonstrating that ACE activity is required for Aβ degradation in living cells.\",\n      \"method\": \"Cloning of ACE from human neuroblastoma cells; site-directed mutagenesis of both active sites; Aβ accumulation assay in Aβ precursor protein-expressing cells; captopril treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site mutagenesis combined with cell-based functional assay and pharmacological inhibition, two orthogonal approaches\",\n      \"pmids\": [\"16154999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ACE enzymatic activity is modulated by its physical interaction with the kinin B2 receptor. Co-expression of somatic ACE with the kinin B2 receptor in CHO cells increased ACE catalytic activity, and this effect was blocked by the B2 receptor antagonist icatibant. Endothelial cells from B2 receptor knockout mice showed decreased ACE activity compared to wild-type cells, confirming the interaction in a physiological context.\",\n      \"method\": \"Co-expression in CHO cells; fluorescent substrate-based ACE activity assay; B2 receptor antagonist pharmacology; endothelial cells from B2 receptor KO mice\",\n      \"journal\": \"Hypertension (Dallas, Tex. : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional interaction demonstrated in both heterologous system and primary KO cells with pharmacological validation; no direct structural evidence of heterodimerization mechanism\",\n      \"pmids\": [\"18212275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ACE activities (both ACE1 and ACE2) are present in porcine ocular tissues including vitreous body, retina, and ciliary body. ACE1 activity was markedly higher in ciliary body than retina, while ACE2 activities were comparable across tissues. ACE-inhibitory tripeptides (Ile-Pro-Pro, Val-Pro-Pro, Leu-Pro-Pro) inhibited ACE1 at ~1/1000th the concentration required to inhibit ACE2, demonstrating distinct pharmacological profiles for the two enzymes in ocular tissue.\",\n      \"method\": \"Fluorometric enzymatic activity assays on porcine ocular tissue fractions; inhibitor concentration-response studies\",\n      \"journal\": \"Journal of ocular pharmacology and therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzymatic activity measurement in tissue fractions; demonstrates ACE1/ACE2 differential localization and pharmacology in eye\",\n      \"pmids\": [\"19232015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Homocysteine (Hcy) metabolites (Hcy-S-S-Hcy and Hcy thiolactone) directly homocysteinylate ACE protein via covalent modification of amino and/or sulfhydryl moieties, resulting in enhanced ACE enzymatic activity. In vitro exposure of purified ACE to these metabolites produced homocysteinylated ACE and increased ACE activity. In isolated coronary and mesenteric arteries exposed to Hcy metabolites or incubated with methionine, ACE activity was similarly enhanced, promoting angiotensin II–NADPH oxidase–superoxide-mediated endothelial dysfunction.\",\n      \"method\": \"In vitro incubation of purified ACE with Hcy metabolites; activity assay; isolated artery vascular function studies; NADPH oxidase inhibitor and AT1 receptor blocker pharmacology\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chemical modification of purified ACE demonstrated with functional consequences in isolated tissue; single study\",\n      \"pmids\": [\"25416191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In C. elegans, reducing activity of acn-1 (the C. elegans ACE homolog) extended mean lifespan, delayed age-related degeneration, and increased stress resistance. The lifespan extension by captopril (an ACE inhibitor) required acn-1 and could not further extend lifespan of acn-1-reduced animals, placing captopril and acn-1 in the same pathway. The ACE/acn-1 longevity pathway is additive with caloric restriction and mitochondrial insufficiency, does not require sir-2.1, hsf-1, or rict-1, but requires daf-16 (FOXO transcription factor).\",\n      \"method\": \"C. elegans genetic epistasis analysis; RNAi knockdown; pharmacological treatment with captopril; lifespan assay; stress resistance assay; double mutant analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in model organism with multiple pathway components tested; orthologous mechanism in C. elegans ACE homolog\",\n      \"pmids\": [\"26918946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Myeloid-specific overexpression of ACE (in ACE10 mice) paradoxically reduced atherosclerotic plaque formation in ApoE-deficient mice fed an atherogenic diet, demonstrating that enhanced macrophage ACE expression is protective against atherosclerosis. Bone marrow transplantation experiments confirmed the effect was hematopoietic cell-autonomous: recipients of ACE10 bone marrow had significantly reduced lesion areas, while ACE-deficient bone marrow had no impact.\",\n      \"method\": \"Transgenic mouse model (ACE10 myeloid ACE overexpression) crossed with ApoE-/- mice; bone marrow transplantation; atherogenic diet; plaque area quantification\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bone marrow transplantation establishes myeloid cell-autonomy; in vivo mouse model with genetic and cellular evidence; single study\",\n      \"pmids\": [\"31615657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Radiation exposure increased ACE activity specifically in lung immune cells (myeloid cells) and promoted generation of reactive oxygen species (ROS) via NADPH oxidase 2 in human monocytes. ACE inhibition with lisinopril blocked radiation-induced ACE activity increases, ROS generation, and reduced ACE-expressing CD11b+ myeloid cell frequency in the lung. In vitro, radiation-induced ROS was blocked by inhibition of either NADPH oxidase 2 or the AT1 receptor, placing ACE upstream of the AT1/NADPH oxidase 2/ROS axis.\",\n      \"method\": \"Rat partial body irradiation and fractionated radiotherapy models; flow cytometry; in vitro human monocyte radiation experiments; NADPH oxidase inhibitor; AT1 receptor blocker; lisinopril treatment; BAL fluid cytokine analysis\",\n      \"journal\": \"International journal of radiation oncology, biology, physics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway position established by pharmacological inhibition at multiple points in both in vivo and in vitro systems; single study\",\n      \"pmids\": [\"35093482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ACE (angiotensin-converting enzyme) defines a subset of granuloma macrophages that are nonpermissive for intracellular Salmonella Typhimurium. ACE+ macrophages in infected mouse spleens are functionally distinct from ACE- macrophage populations; their abundance anticorrelates with tissue bacterial burden. TNF neutralization preferentially depleted ACE+ macrophages, linking TNF signaling to maintenance of this antimicrobial macrophage population.\",\n      \"method\": \"Single-cell RNA sequencing; flow cytometry sorting; S. Typhimurium infection mouse model; TNF neutralization experiment; spatial localization analysis\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq identity with functional correlation to bacterial burden; TNF neutralization experiment; single study without direct ACE enzymatic mechanism\",\n      \"pmids\": [\"36608122\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACE (angiotensin-converting enzyme, EC 3.4.15.1) is a membrane-bound zinc dipeptidyl carboxypeptidase with two independently catalytically active domains (N and C) arising from gene duplication; the C-domain preferentially hydrolyzes angiotensin I to angiotensin II and bradykinin to inactive fragments (both requiring zinc, chloride activation, and a catalytic Glu residue), while the N-domain has high selectivity for the hemoregulatory peptide AcSDKP; both domains contribute to Aβ degradation in cells; the enzyme's activity is enhanced by covalent homocysteinylation and by heterodimerization with the kinin B2 receptor; myeloid ACE overexpression reduces atherosclerosis and defines an antimicrobial macrophage state, while the C. elegans ortholog (acn-1) regulates aging through a daf-16-dependent pathway distinct from caloric restriction and mitochondrial pathways.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ACE (angiotensin-converting enzyme) is a zinc-dependent dipeptidyl carboxypeptidase that occupies a central position in vasoactive peptide metabolism, hematopoietic stem cell biology, and innate immune defense. Somatic ACE contains two homologous catalytic domains exhibiting negative cooperativity for angiotensin I and angiotensin-(1-7), while a single-domain testicular isoform is essential for male fertility [PMID:15283675, PMID:12676162]. Beyond its classical role in converting angiotensin I to angiotensin II and inactivating bradykinin on the endothelial surface, ACE (CD143) marks functionally superior hematopoietic stem cells throughout human ontogeny and identifies granuloma macrophages that restrict intracellular bacterial growth [PMID:17993616, PMID:22282502, PMID:36608122]. ACE activity is further modulated by heterodimerization with the bradykinin B2 receptor, by homocysteinylation of active-site residues, and by radiation-induced activation in myeloid cells through an AT1 receptor–NADPH oxidase–ROS circuit that drives tissue injury [PMID:18212275, PMID:25416191, PMID:35093482].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Establishing that ACE on the pulmonary endothelial surface is responsible for both angiotensin I conversion and bradykinin inactivation in vivo provided the foundational dual-substrate model for ACE function.\",\n      \"evidence\": \"Serum ACE activity measurement in an E. coli sepsis baboon model correlated with hemodynamic parameters\",\n      \"pmids\": [\"6315257\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Correlative in vivo study without direct enzyme inhibition or genetic confirmation\", \"Does not distinguish endothelial ACE from soluble ACE contributions\", \"Mechanism of ACE depletion during sepsis not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that ACE inhibitors directly activate the bradykinin B1 receptor through its HEXXH motif, independent of ACE enzymatic activity, revealed an off-target pharmacological pathway for ACE inhibitor drugs.\",\n      \"evidence\": \"Cell-based assay with recombinant B1 receptor; site-directed mutagenesis of H195; Ca²⁺ and NO measurement\",\n      \"pmids\": [\"12489793\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; no independent replication reported\", \"In vivo relevance of ACE inhibitor–B1 receptor interaction not tested\", \"Structural basis of ACE inhibitor binding to B1 receptor HEXXH motif not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mouse knockout studies established that the single-domain testicular ACE isoform is essential for male fertility, distinguishing the germinal isoform from the dual-domain somatic form and confirming non-redundant biological roles.\",\n      \"evidence\": \"Mouse ACE gene knockout with fertility phenotype assessment\",\n      \"pmids\": [\"12676162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate(s) whose cleavage is required for sperm function not fully identified\", \"Mechanism by which tACE supports fertilization unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Quantitative kinetic analysis of the separate N- and C-domains revealed that both domains cleave angiotensin I with similar efficiency but exhibit negative cooperativity, establishing that domain–domain communication regulates catalytic output.\",\n      \"evidence\": \"In vitro kinetic assays with purified N- and C-domain preparations, active-site titration with tight-binding inhibitors\",\n      \"pmids\": [\"15283675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for negative cooperativity between domains not resolved\", \"Physiological relevance of domain selectivity for different substrates in vivo unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Gene copy-number titration in mice linked ACE dosage to body weight and adiposity, and mass spectrometry identified adipose oligopeptides as ACE substrates, expanding ACE function beyond classical vasoactive peptide processing.\",\n      \"evidence\": \"ACE copy-number variant mice on high-fat diet; LC-ESI-MS/MS substrate identification; in vitro PKC phosphorylation assay\",\n      \"pmids\": [\"15522949\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality between identified oligopeptides and body weight control not demonstrated in vivo\", \"Downstream signaling pathway linking ACE-generated peptides to adiposity regulation not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of ACE (CD143) as the BB9 antigen on human hematopoietic stem cells, with ACE+ cord blood cells engrafting 10-fold more efficiently in xenotransplantation, established ACE as a functional HSC marker and implicated ACE in stem cell biology beyond peptide metabolism.\",\n      \"evidence\": \"Flow cytometry; protein microsequencing of immunoprecipitated BB9; NOD/SCID xenotransplantation of sorted CD34+BB9+ vs CD34+BB9− cells\",\n      \"pmids\": [\"17993616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ACE enzymatic activity is required for HSC engraftment advantage not tested\", \"Mechanism by which ACE expression confers functional superiority to HSCs unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that B2 receptor heterodimerization augments ACE catalytic activity — abolished by B2 antagonism and reduced in B2-KO endothelial cells — revealed receptor-level allosteric regulation of ACE enzymatic function.\",\n      \"evidence\": \"Fluorescent substrate assay in CHO cells coexpressing ACE and B2 receptor; B2-KO mouse endothelial cell comparison\",\n      \"pmids\": [\"18212275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and structural interface of ACE–B2 heterodimer not defined\", \"In vivo hemodynamic consequence of this interaction not quantified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extending the HSC finding to embryonic development, ACE+ cells in the para-aortic splanchnopleura, fetal liver, and bone marrow were shown to possess long-term multilineage repopulating capacity, establishing ACE as a conserved marker of definitive hematopoietic precursors.\",\n      \"evidence\": \"Cell sorting of CD34+ACE+ populations; long-term culture-initiating cell assay; NOD/SCID xenotransplantation\",\n      \"pmids\": [\"22282502\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ACE is functionally required for hematopoietic specification or merely marks HSCs remains untested by loss-of-function\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstration that homocysteine metabolites directly modify ACE active-site residues and enhance enzymatic activity provided a biochemical link between hyperhomocysteinemia and endothelial dysfunction via augmented angiotensin II generation.\",\n      \"evidence\": \"In vitro incubation of purified ACE with homocysteine thiolactone; enzyme activity assay; isolated vessel bioassay with NADPH oxidase/AT1 inhibitors\",\n      \"pmids\": [\"25416191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Sites of homocysteinylation on ACE not mapped at residue level\", \"In vivo confirmation of enhanced ACE activity in hyperhomocysteinemic models not provided\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genetic epistasis in C. elegans showed that ACE ortholog acn-1 limits lifespan through a daf-16/FOXO-dependent pathway additive with insulin signaling and caloric restriction, placing ACE in an evolutionarily conserved longevity axis.\",\n      \"evidence\": \"RNAi/mutant lifespan assays; double-mutant analysis with daf-2, age-1, and eat-2 in C. elegans\",\n      \"pmids\": [\"26918946\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate of acn-1 relevant to longevity not identified\", \"Whether mammalian ACE inhibition similarly extends lifespan not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining radiation-induced ACE activation in lung myeloid cells via an AT1/NADPH oxidase 2/ROS feedforward loop established a cell-autonomous mechanism for ACE-driven radiation pneumonitis and showed ACE inhibition as a therapeutic intervention.\",\n      \"evidence\": \"Rat partial-body irradiation model; in vitro human monocyte irradiation with pharmacological inhibitors; flow cytometry and ROS measurement\",\n      \"pmids\": [\"35093482\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional vs. post-translational mechanism of radiation-induced ACE upregulation not dissected\", \"Whether other ACE substrates beyond angiotensin contribute to myeloid ROS not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Single-cell transcriptomics during persistent Salmonella infection revealed that ACE+ granuloma macrophages are bacterially nonpermissive, and TNF neutralization depletes this population, connecting ACE to innate immune containment of intracellular pathogens.\",\n      \"evidence\": \"scRNAseq; S. enterica mouse infection model; anti-TNF treatment; bacterial burden quantification\",\n      \"pmids\": [\"36608122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ACE enzymatic activity is directly bactericidal or whether ACE marks a differentiation state is not resolved\", \"Substrate cleaved by macrophage ACE during infection not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which ACE enzymatic activity contributes to HSC function, macrophage antimicrobial activity, and longevity regulation remains undefined; the critical substrates and downstream effectors in these non-canonical contexts have not been identified.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No substrate identified for ACE's HSC or immune functions\", \"Structural basis for negative cooperativity between somatic ACE domains not resolved\", \"Whether ACE catalytic activity vs. surface expression mediates non-RAS functions untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 7, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BDKRB2\", \"AGTR1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ACE is a membrane-bound zinc dipeptidyl carboxypeptidase that converts angiotensin I to angiotensin II and inactivates bradykinin, thereby serving as a central regulator of the renin–angiotensin and kallikrein–kinin systems [PMID:4322742, PMID:15283675]. The somatic enzyme contains two homologous catalytic domains (N and C), each bearing a zinc-coordinating HEXXH motif and requiring chloride for activation; the C-domain preferentially hydrolyzes angiotensin I, whereas the N-domain exhibits high selectivity for the hemoregulatory peptide AcSDKP, and both domains cooperate in degrading amyloid-β peptides [PMID:1851160, PMID:7876104, PMID:16154999]. A testis-specific isoform corresponding to the C-domain alone is transcribed from an alternative promoter in spermatids [PMID:2554286]. Beyond its classical vascular role, myeloid ACE expression defines an antimicrobial macrophage subset that restricts intracellular Salmonella and attenuates atherosclerosis, linking ACE to innate immune function [PMID:31615657, PMID:36608122].\",\n  \"teleology\": [\n    {\n      \"year\": 1970,\n      \"claim\": \"Establishing ACE's core enzymatic identity as a dipeptidyl carboxypeptidase resolved how angiotensin I is activated and bradykinin inactivated in a single catalytic step.\",\n      \"evidence\": \"In vitro enzymatic assay with purified enzyme measuring C-terminal dipeptide release\",\n      \"pmids\": [\"4322742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of substrate recognition unknown\",\n        \"Number and independence of catalytic sites not yet established\"\n      ]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Demonstration that ACE also cleaves neuropeptides (substance P, neurotensin) in a chloride-dependent manner broadened its substrate repertoire beyond the renin–angiotensin system and identified an essential active-site arginine residue.\",\n      \"evidence\": \"In vitro enzymatic assay with purified human ACE; HPLC product analysis; chemical modification of arginine\",\n      \"pmids\": [\"6208535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No three-dimensional structure to explain chloride activation mechanism\",\n        \"Physiological significance of neuropeptide cleavage not demonstrated in vivo\"\n      ]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Cloning of full-length somatic ACE cDNA revealed the two-domain architecture arising from gene duplication, each carrying an HEXXH zinc-binding motif, fundamentally reframing ACE as a tandem metallopeptidase.\",\n      \"evidence\": \"cDNA cloning and sequencing from human vascular endothelial cells\",\n      \"pmids\": [\"2849100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Catalytic independence of the two domains not yet proven\",\n        \"Whether the testis-specific transcript encodes a single-domain enzyme unclear\"\n      ]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Cloning of testicular ACE showed it corresponds to the C-domain alone, transcribed from an alternative promoter, proving the C-domain is independently catalytically sufficient.\",\n      \"evidence\": \"cDNA cloning and sequencing of human testicular ACE; sequence comparison with somatic isoform\",\n      \"pmids\": [\"2554286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional role of tACE in fertilization not established\",\n        \"Substrate preferences of isolated C-domain vs. full-length enzyme unknown\"\n      ]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Site-directed mutagenesis demonstrated that both N- and C-domains are independently active, each requiring its own zinc-binding histidines and catalytic glutamate, and that the two domains differ in chloride sensitivity and kinetic parameters.\",\n      \"evidence\": \"Site-directed mutagenesis of active-site residues in each domain; expression in CHO cells; enzymatic assay\",\n      \"pmids\": [\"1851160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for differential chloride activation not resolved\",\n        \"Whether negative cooperativity between domains occurs with physiological substrates unknown\"\n      ]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying AcSDKP as a highly N-domain-selective substrate established the first clear functional distinction between the two active sites, linking the N-domain specifically to hematopoietic stem cell regulation.\",\n      \"evidence\": \"In vitro kinetic assay using wild-type and single-active-site mutant ACE; domain-specific antibody inhibition\",\n      \"pmids\": [\"7876104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo significance of N-domain AcSDKP hydrolysis not directly tested\",\n        \"Whether other N-domain-selective substrates exist is unknown\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showing that ACE degrades amyloid-β peptide at a defined cleavage site and inhibits Aβ aggregation expanded ACE's roles to neurodegeneration-relevant biology.\",\n      \"evidence\": \"In vitro cleavage with purified ACE; HPLC, MALDI-TOF/MS product identification; EM fibril assay; cytotoxicity assay\",\n      \"pmids\": [\"11604391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo relevance in brain parenchyma not established\",\n        \"Relative contribution of N- vs. C-domain to Aβ degradation unknown at this point\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The 2.0 Å crystal structure of tACE–lisinopril complex revealed an unexpected fold related to neurolysin rather than carboxypeptidase A, providing the structural basis for inhibitor binding and rational domain-selective inhibitor design.\",\n      \"evidence\": \"X-ray crystallography at 2.0 Å resolution of human tACE in complex with lisinopril\",\n      \"pmids\": [\"12540854\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"N-domain crystal structure not yet determined\",\n        \"Structural explanation for negative cooperativity between domains still missing\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Comprehensive kinetic profiling of both ACE domains, ACE2, and neprilysin with angiotensin peptides established quantitative substrate preferences and demonstrated negative cooperativity between the two ACE active sites, clarifying the enzyme's role in the angiotensin cascade relative to ACE2.\",\n      \"evidence\": \"In vitro kinetics with active-site-titrated purified enzymes; fluorogenic substrate assays\",\n      \"pmids\": [\"15283675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular mechanism of negative cooperativity not structurally defined\",\n        \"In vivo contributions of each domain to angiotensin processing not separated\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that both ACE domains contribute to Aβ degradation in living cells, and that pharmacological ACE inhibition causes Aβ accumulation, established a cell-biological context for ACE's amyloidolytic activity.\",\n      \"evidence\": \"Active-site mutagenesis; Aβ accumulation assay in neuroblastoma cells expressing APP; captopril treatment\",\n      \"pmids\": [\"16154999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No in vivo brain model confirming ACE-dependent Aβ clearance\",\n        \"Relative importance of ACE vs. other Aβ-degrading enzymes not quantified\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that the bradykinin B2 receptor physically interacts with ACE and enhances its catalytic activity introduced receptor-mediated allosteric regulation of ACE, validated by B2 receptor knockout endothelial cells.\",\n      \"evidence\": \"Co-expression in CHO cells; fluorescent ACE activity assay; B2 receptor antagonist; B2 receptor KO mouse endothelial cells\",\n      \"pmids\": [\"18212275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct structural evidence of ACE–B2 receptor complex\",\n        \"Stoichiometry and binding interface unknown\",\n        \"Not independently replicated\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Covalent homocysteinylation of ACE by homocysteine metabolites was shown to enhance ACE activity and promote angiotensin II–NADPH oxidase–superoxide-mediated endothelial dysfunction, providing a molecular link between hyperhomocysteinemia and vascular disease.\",\n      \"evidence\": \"In vitro modification of purified ACE with Hcy metabolites; isolated artery vascular function studies with pharmacological inhibitors\",\n      \"pmids\": [\"25416191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific modified residues not identified\",\n        \"In vivo demonstration of homocysteinylated ACE in hyperhomocysteinemia not provided\",\n        \"Single study without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genetic epistasis in C. elegans placed the ACE ortholog acn-1 in a daf-16/FOXO-dependent longevity pathway distinct from caloric restriction and mitochondrial insufficiency, extending ACE biology to aging regulation.\",\n      \"evidence\": \"C. elegans RNAi; captopril treatment; lifespan assay; double mutant epistasis analysis\",\n      \"pmids\": [\"26918946\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether mammalian ACE similarly regulates lifespan is untested\",\n        \"Substrate(s) of acn-1 mediating longevity are unidentified\",\n        \"Catalytic vs. non-catalytic roles of acn-1 not distinguished\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Myeloid-specific ACE overexpression was shown to be atheroprotective in ApoE-deficient mice through bone marrow transplantation, establishing a cell-autonomous role for macrophage ACE in limiting atherosclerosis.\",\n      \"evidence\": \"ACE10 transgenic mice crossed with ApoE−/−; bone marrow transplantation; atherogenic diet; plaque quantification\",\n      \"pmids\": [\"31615657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Downstream effector peptides or substrates in macrophages not identified\",\n        \"Whether N-domain, C-domain, or both mediate the atheroprotective effect is unknown\",\n        \"Single study without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Single-cell transcriptomics identified ACE as a marker of a distinct antimicrobial macrophage subset in granulomas that restricts intracellular Salmonella, with TNF signaling maintaining this population, linking ACE to innate immune defense.\",\n      \"evidence\": \"scRNA-seq; flow cytometry; S. Typhimurium mouse infection model; TNF neutralization\",\n      \"pmids\": [\"36608122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether ACE enzymatic activity is required for the antimicrobial phenotype is untested\",\n        \"Mechanism by which ACE+ macrophages restrict bacteria is unknown\",\n        \"Not replicated in human infection settings\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of inter-domain negative cooperativity in full-length somatic ACE, the identity of ACE substrates mediating macrophage antimicrobial and atheroprotective functions, and whether ACE regulates mammalian lifespan through a FOXO-dependent pathway as suggested by the C. elegans ortholog.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Full-length somatic ACE crystal structure with both domains resolved is lacking\",\n        \"Macrophage-specific ACE substrates not identified\",\n        \"Mammalian aging phenotype of ACE modulation not tested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 4, 5, 9, 12]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 5, 9, 12, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [8, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 12, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 5, 9, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"BDKRB2\",\n      \"AGT\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}